title: Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer. Preliminary report on acute toxicity.
abstract: OBJECTIVE
  Toxicity of an accelerated 7 days per week fractionation schedule (arm A) was evaluated and compared with a conventional 5 days per week treatment (arm B) in a randomized trial.
  
  
  METHODS
  Forty-four patients with squamous cell carcinoma of the head and neck in stage T2-4Nzero-1Mzero were included in the study. Total dose and dose per fraction of 2.0 Gy given once-a-day at 24 h intervals were the same in both arms of the trial. The only difference was the overall treatment time being 5 weeks in arm A and 7 weeks in arm B.
  
  
  RESULTS
  Analysis of severe mucosal reactions shows significant difference between arm A and B, with regard to both maximum score and duration of severe mucositis. Confluent mucositis (score > 15 according to the Dische system) lasting longer than 3 weeks developed in 48% of patients in arm A and only in 5% in arm B. In group A seven (30%) late effects (osteo- and soft tissue necrosis) occurred during 7-12 month follow-up with two reactions (10%) in group B being suspected as late effects. There was significant association between acute reactions and late effects in arm A, suggesting that the late effects are consequential.
  
  
  CONCLUSIONS
  The high incidence of severe acute reactions and consequential late effects suggests that the accelerated treatment in arm A (using daily fractions of 2.0 Gy, 7 days per week) gives unacceptable toxicity.
authors.affiliation: Centre of Oncology, M. Skłodowska-Curie Memorial Institute, Gliwice, Poland.
authors.forename: B
authors.initials: B
authors.lastname: Maciejewski
authors.forename: K
authors.initials: K
authors.lastname: Skladowski
authors.forename: B
authors.initials: B
authors.lastname: Pilecki
authors.forename: J M
authors.initials: JM
authors.lastname: Taylor
authors.forename: R H
authors.initials: RH
authors.lastname: Withers
authors.forename: L
authors.initials: L
authors.lastname: Miszczyk
authors.forename: A
authors.initials: A
authors.lastname: Zajusz
authors.forename: R
authors.initials: R
authors.lastname: Suwinski
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D003238:Connective Tissue / Q000473:pathology; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D007249:Inflammation / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000528:radiation effects; D009336:Necrosis; D010020:Osteonecrosis / Q000209:etiology; D011832:Radiation Injuries / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D015431:Weight Loss